BLOG
FDA Warning on Xylazine: Mitigating Human Risk
FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
Recent Articles
Minnesota’s New Prescription Drug Price Transparency Reporting: What You Need to Know
Minnesota's New Prescription Drug Price Transparency Reporting: What You Need to Know | by: Sumeet Singh, Founder & Chairman | Article Posted:...
Important Updates from the Alabama Board of Pharmacy on Facility Applications and Renewals
FDA Important Updates from the Alabama Board of Pharmacy on Facility Applications and Renewals | by: Sumeet Singh, Founder & Chairman | Article...
FDA Extends Enforcement Deadline for Drug Supply Chain Security Act (DSCSA) Requirements
FDA Extends Enforcement Deadline for Drug Supply Chain Security Act (DSCSA) Requirements | by: Sumeet Singh, Founder & Chairman | Article...
A Comprehensive Guide to Pharmaceutical State Licensing Renewals
A Comprehensive Guide to Pharmaceutical State Licensing Renewals | by: Maria Pennings, VP of Professional Services | Article Posted: August 6, 2023...
Kentucky Has Filed Amendments to Regulations and/or New Regulations
Kentucky has Filed Amendments to Regulations and/or New Regulations | by: Deneen Fumich, RPh | Article Posted: July 27, 2023 | Kentucky has filed...
New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies
New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies | by: Sumeet Singh, Founder & Chairman | Article Posted: July 5,...
